| Name | Title | Contact Details |
|---|
Carrington Fox is a boutique executive search firm founded in 2001, based in New York City. The company specializes in human capital solutions for global financial markets, focusing on executive and contingent search mandates. With a team of approximately 25 to 50 employees, Carrington Fox generates an estimated annual revenue between $5 million and $25 million. The firm serves clients in investment banking, private equity, hedge funds, tax, accounting, and quantitative analytics. They emphasize long-term partnerships, aiming to understand client needs and candidate aspirations deeply. Carrington Fox is known for its niche expertise in front-office financial roles and quantitative disciplines, providing tailored recruitment processes with a commitment to confidentiality and efficiency.
MedChemExpress offers a wide range of high-quality life science biochemicals, including novel bioactive compounds, recombinant proteins, dye reagents, peptides and natural compounds for laboratory and scientific use. We take pride in offering only the highest-grade products. Product identity, quality, purity and activity are assured by our robust quality control programs and procedures. We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.
City First Bank is a commercial community development bank, the largest Black-led Minority Depository Institution, and a certified as B Corp with branches and headquarters in Los Angeles, CA and Washington, DC; channeling intentional capital to low- and moderate-income neighborhoods; investing in multifamily affordable housing, nonprofits and small business development. We offer a unique platform for impact depositors and institutional investors to see value in strengthening LMI communities through the provision of capital. NASDAQ: BYFC
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".